Dyslipidemia (High Cholesterol & Triglycerides) Protocol

CardiovascularStrong Evidence

supplements

Primary

Supporting

Grade A

185

Studies

Primary Stack

Core supplements with strongest evidence

Omega-3 Fatty AcidsA

2-4g EPA/DHA daily (for triglycerides)

Reduces triglyceride synthesis in liver, increases VLDL clearance, and modestly raises HDL

Apolipoprotein A↓Triglycerides↑High-density lipoprotein (HDL)↓Low-density lipoprotein (LDL)↓Total cholesterol

45 studies5,000 participants

Supporting Studies (2)

PMID: 27159202 - Omega-3 fatty acids and lipid parameters: meta-analysis (2016)PMID: 30415628 - REDUCE-IT: Icosapent ethyl for elevated triglycerides (2019)

BerberineA

500mg 2-3x daily with meals

Inhibits PCSK9 to increase LDL receptor expression, activates AMPK to reduce lipid synthesis

↓Apolipoprotein B↓Triglycerides↓Low-density lipoprotein (LDL)↑High-density lipoprotein (HDL)↓Total cholesterol

25 studies2,500 participants

Supporting Studies (2)

PMID: 22529926 - Berberine for dyslipidemia: meta-analysis (2012)PMID: 28268234 - Berberine effects on cholesterol: systematic review (2017)

Supporting Stack

Additional supplements for enhanced results

Soluble Fiber (Beta-glucan/Psyllium)A

5-15g daily (including 3g beta-glucan)

Binds bile acids in intestine, forcing liver to use cholesterol for new bile acid synthesis

↓Blood glucose↓Blood Pressure↓Low-density lipoprotein (LDL)↓Total cholesterol↓Weight

30 studies2,500 participants

Supporting Studies (2)

PMID: 21631511 - Soluble fiber for LDL cholesterol: meta-analysis (2011)PMID: 26269239 - Beta-glucan for cholesterol: systematic review (2015)

Plant Sterols/StanolsA

2-3g daily with meals

Compete with cholesterol for intestinal absorption, reducing dietary and biliary cholesterol uptake

40 studies4,000 participants

Supporting Studies (1)

PMID: 19939984 - Plant sterols and stanols for cholesterol: meta-analysis (2009)

Red Yeast RiceA

1200-2400mg daily (providing 3-10mg monacolin K)

Contains monacolin K (natural lovastatin) that inhibits HMG-CoA reductase

Apolipoprotein A↑High-density lipoprotein (HDL)↓Low-density lipoprotein (LDL)↓Total cholesterol↓Triglycerides

20 studies2,000 participants

Supporting Studies (1)

PMID: 20479151 - Red yeast rice for hyperlipidemia: systematic review (2010)

Niacin (Vitamin B3)B

1-2g daily (extended-release, with monitoring)

Inhibits lipolysis in adipose tissue, reduces VLDL secretion, and raises HDL significantly

↑Apolipoprotein A↓Apolipoprotein B↑High-density lipoprotein (HDL)↓Triglycerides↑Bilirubin

25 studies3,000 participants

Supporting Studies (1)

PMID: 19749196 - Niacin for dyslipidemia: systematic review (2009)

How This Protocol Works

Simple Explanation

Dyslipidemia refers to abnormal blood lipid levels—high LDL cholesterol ('bad cholesterol'), high triglycerides, or low HDL cholesterol ('good cholesterol'). These abnormalities significantly increase cardiovascular disease risk. While statins are the gold standard for high LDL, several supplements have strong evidence for improving lipid profiles, especially for those who can't tolerate statins or need additional lipid-lowering.

•Omega-3 Fatty Acids are the most effective supplement for lowering triglycerides. At doses of 2-4g daily, they can reduce triglycerides by 15-30%. The REDUCE-IT trial showed that high-dose EPA (4g/day) also reduced cardiovascular events. They work by reducing the liver's production of triglyceride-rich VLDL particles. Effects on LDL and HDL are modest.

•Berberine is remarkably effective for dyslipidemia—it can lower LDL cholesterol by 20-25%, similar to a low-dose statin. It works through a unique mechanism: inhibiting PCSK9, which increases the number of LDL receptors on liver cells that remove LDL from the blood. It also activates AMPK, reducing cholesterol and triglyceride synthesis.

•Soluble Fiber (Beta-glucan/Psyllium) lowers LDL cholesterol by binding bile acids in the intestine. The liver must then use cholesterol to make new bile acids, reducing circulating LDL. The FDA allows health claims for oat beta-glucan—3g daily can lower LDL by 5-10%.

•Plant Sterols/Stanols are structurally similar to cholesterol and compete with it for absorption. Taking 2-3g daily with meals can reduce LDL by 6-15%. They're often added to margarine spreads and yogurt drinks.

•Red Yeast Rice contains monacolin K, which is chemically identical to the statin lovastatin. It can lower LDL by 15-25%. However, quality varies widely between products—some contain little active ingredient, others have high levels plus potential contaminants.

•Niacin (Vitamin B3) is the most effective supplement for raising HDL—it can increase HDL by 15-35%. It also lowers triglycerides and LDL. However, it causes flushing in most people, and the extended-release form is better tolerated.

Expected timeline: Omega-3 effects on triglycerides visible in 4-6 weeks. LDL reductions from berberine, fiber, and sterols appear in 4-8 weeks. Retest lipid panel after 8-12 weeks of supplementation.

Clinical Perspective

Dyslipidemia is classified as elevated LDL-C (>130 mg/dL), elevated triglycerides (>150 mg/dL), reduced HDL-C (<40 mg/dL in men, <50 in women), or combined hyperlipidemia. Pathophysiology involves hepatic VLDL overproduction, impaired LDL receptor-mediated clearance, or intestinal cholesterol hyperabsorption. LDL-C is primary target; non-HDL-C and apoB are secondary. This protocol addresses multiple lipid abnormalities.

•Omega-3 Fatty Acids (A-grade): EPA/DHA reduce hepatic VLDL synthesis and accelerate VLDL catabolism. Dose-dependent triglyceride reduction: 2g reduces TG ~15%, 4g reduces TG ~30%. Meta-analysis confirms robust TG-lowering effect (PMID: 27159202). REDUCE-IT trial: 4g icosapent ethyl (purified EPA) reduced CV events 25% in patients with elevated TG on statins (PMID: 30415628). Minimal LDL-lowering; may slightly raise LDL with mixed EPA/DHA products.

•Berberine (A-grade): Unique mechanism: increases hepatic LDL receptor expression by inhibiting PCSK9 (same pathway as PCSK9 inhibitors like evolocumab). Also activates AMPK, reducing SREBP-1c-mediated lipogenesis. Meta-analysis: reduces LDL-C by 25 mg/dL (20-25%), TG by 35 mg/dL, increases HDL modestly (PMID: 22529926). Comparable to ezetimibe for LDL-lowering. May interact with CYP3A4 substrates.

•Soluble Fiber (A-grade): Viscous fibers (beta-glucan, psyllium) bind bile acids, interrupting enterohepatic circulation. Hepatic bile acid synthesis upregulated, increasing LDL receptor expression. FDA-approved health claim: 3g/day oat beta-glucan reduces CHD risk. Meta-analysis: soluble fiber reduces LDL-C ~5% (4 mg/dL per gram) (PMID: 21631511). Also improves glucose tolerance.

•Plant Sterols/Stanols (A-grade): Structural analogs of cholesterol. Displace cholesterol from intestinal micelles, reducing absorption by ~50%. Meta-analysis: 2-3g/day reduces LDL-C by 6-15% (~10% average) (PMID: 19939984). Effects additive to statins. Can reduce absorption of fat-soluble vitamins—supplement vitamin D if needed.

•Red Yeast Rice (A-grade): Contains monacolin K (lovastatin), HMG-CoA reductase inhibitor. Variable content 0.1-10mg per dose depending on product. Systematic review: 2400mg/day (10mg monacolin K) reduces LDL-C by ~25% (PMID: 20479151). CAUTION: Same mechanism as statins—similar contraindications and myopathy risk. Quality control issues with citrinin (nephrotoxin) contamination. Requires liver monitoring.

•Niacin (B-grade): Inhibits adipocyte lipolysis (GPR109A receptor), reducing FFA flux to liver and VLDL synthesis. Also inhibits hepatocyte DGAT2. Raises HDL 15-35% by reducing HDL catabolism. Meta-analysis confirms lipid benefits (PMID: 19749196). However, AIM-HIGH and HPS2-THRIVE trials showed no incremental CV benefit when added to statins. Flushing common—use extended-release, aspirin pre-treatment. Contraindicated in gout, hepatic disease.

Biomarker targets: LDL-C (<100, <70 for very high risk), non-HDL-C (<130), apoB (<90), TG (<150), HDL-C (>40 M/>50 F), TC/HDL ratio (<4), Lp(a) (assess once).

Protocol notes: Statins remain first-line for elevated LDL-C with ASCVD risk. Supplements appropriate for statin intolerance, adjunctive therapy, or isolated TG elevation. Berberine: effective alternative; monitor hepatic enzymes. Red yeast rice: essentially low-dose statin—same precautions apply; avoid with statin therapy. Omega-3s: prescription icosapent ethyl (Vascepa) for maximal TG reduction and CV benefit. Plant sterols: distribute intake across meals. Address diet (Mediterranean, limit saturated/trans fat), exercise, weight management. Recheck lipids 8-12 weeks after intervention.

View All Protocols